Intrinsic Imaging provides imaging core lab services in support of central nervous system (CNS) clinical trials. In neurological, neurodegenerative, cerebrovascular, psychiatric and spinal indications, our subspecialty neuroradiologists apply advanced quantitative neuroimaging and standardized imaging methods, providing sponsors with a sound basis for evaluating safety and efficacy. This support extends to trials of neurovascular and neurointerventional devices.
At Intrinsic Imaging, our CNS Imaging division brings together more than 100 board-certified, fellowship-trained neuroradiologists with expertise across the full spectrum of brain and spine disease, including Alzheimer's disease and other dementias, multiple sclerosis, Parkinson's and Huntington's diseases, epilepsy, stroke and cerebrovascular disease, traumatic brain injury, spinal cord injury, and degenerative disorders of the spine. Brain and spinal tumors are assessed in collaboration with our Oncology Imaging division.
Intrinsic Imaging supports CNS imaging endpoints across an extensive range of modalities, including structural and functional MRI, MRA, CT and CTA, CT and MR perfusion, diffusion and diffusion tensor imaging, PET and other nuclear imaging techniques, spectroscopy, catheter angiography, and transcranial Doppler ultrasound. Our teams work closely with sponsors from protocol development and imaging charter design through database lock to establish standardized acquisition requirements, qualify and train imaging sites, define quantitative and qualitative assessment methodologies, conduct blinded independent central reviews, and implement adjudication procedures designed to minimize inter- and intra-reader variability.
By combining neuroradiology subspecialty expertise with standardized imaging protocols, centralized quality control, and reproducible quantitative assessment, Intrinsic Imaging helps sponsors generate reliable, scientifically robust imaging data suitable for longitudinal endpoint evaluation, clinical development decision-making, and global regulatory submissions. This rigor is particularly valuable in CNS trials, in which subtle changes in anatomy, lesion burden, perfusion, diffusion, metabolism, or other imaging biomarkers may provide critical evidence of disease progression or therapeutic response.